## Anticoagulation and Rate Control in AF with Structural Heart Disease ### Clinical Context This patient has **rheumatic mitral stenosis** (structural heart disease) with new-onset AF. The presence of structural heart disease fundamentally changes management: 1. **Anticoagulation is mandatory** — high thromboembolic risk 2. **DOACs are contraindicated** in significant mitral stenosis 3. **Bridging anticoagulation is required** — warfarin has delayed onset 4. **Rate control is necessary** — to reduce symptoms and prevent tachycardia-induced cardiomyopathy ### Key Point: Structural Heart Disease and Anticoagulation **High-Yield:** In AF with structural heart disease (rheumatic valve disease, prosthetic valve, significant LV dysfunction), **warfarin is the anticoagulant of choice**. DOACs are contraindicated because they are not adequately studied in these populations and are ineffective in mitral stenosis. **Mnemonic: DOAC Contraindications in AF — SAVE ME:** - **S**evere renal impairment (CrCl < 15 mL/min) - **A**ctive bleeding or HAS-BLED ≥ 3 - **V**alvular AF (rheumatic disease, prosthetic valve) - **E**nd-stage liver disease - **M**itral stenosis (moderate to severe) - **E**levated INR (on warfarin already) ### Management Algorithm for AF + Structural Heart Disease ```mermaid flowchart TD A[AF + Structural Heart Disease]:::outcome --> B{Haemodynamically stable?}:::decision B -->|No| C[Urgent cardioversion]:::urgent B -->|Yes| D[Initiate rate control]:::action D --> E[IV diltiazem/verapamil or beta-blocker]:::action E --> F[Initiate anticoagulation]:::action F --> G{Valve disease present?}:::decision G -->|Rheumatic/Prosthetic| H[Warfarin + IV heparin bridge]:::action G -->|No structural disease| I[Warfarin OR DOAC]:::action H --> J[Target INR 2–3]:::outcome I --> K[Continue rate control]:::action ``` ### Anticoagulation Strategy: Bridging **Key Point:** Warfarin takes 5–7 days to achieve therapeutic INR. During this lag period, **IV unfractionated heparin (UFH) or LMWH bridging** is required to prevent thromboembolic events. | Anticoagulant | Onset | Use in Mitral Stenosis | Bridging? | |---|---|---|---| | **Warfarin** | 5–7 days | **Gold standard** | Yes, requires bridge | | **DOAC (dabigatran, apixaban, rivaroxaban)** | 1–2 hours | **Contraindicated** | No — ineffective in MS | | **IV UFH** | Immediate | **Bridging agent** | Yes, until INR 2–3 | | **LMWH** | 4–6 hours | **Bridging agent** | Yes, until INR 2–3 | **Clinical Pearl:** The bridging period typically lasts 5–7 days (until INR is therapeutic on warfarin for 24 hours). During bridging, both heparin and warfarin are given concurrently. ### Why Rate Control First? **High-Yield:** Rate control should be initiated **simultaneously** with anticoagulation, not sequentially: - Reduces symptoms (palpitations, dyspnea) - Prevents tachycardia-induced cardiomyopathy - Improves haemodynamic stability - Preferred agents: IV diltiazem, verapamil, or beta-blockers (metoprolol) ### Why NOT DOACs in This Patient? **Warning:** DOACs (dabigatran, apixaban, rivaroxaban, edoxaban) are **absolutely contraindicated** in moderate-to-severe mitral stenosis because: 1. **Inadequate anticoagulation:** Reduced bioavailability in the setting of mitral stenosis 2. **Lack of evidence:** Not studied in rheumatic AF 3. **Increased stroke risk:** Higher thromboembolic events reported 4. **Regulatory guidance:** ESC and ACC/AHA guidelines explicitly recommend warfarin **Key Point:** Mild mitral regurgitation or aortic valve disease is NOT a contraindication to DOACs, but mitral stenosis (any degree) is. ### Why NOT Immediate Cardioversion? **Clinical Pearl:** Elective cardioversion is deferred in AF > 48 hours duration without anticoagulation because of the risk of thromboembolic stroke (up to 5–7%). This patient requires at least 3 weeks of anticoagulation (or TOE-guided cardioversion) before rhythm control is attempted. [cite:Harrison 21e Ch 226]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.